Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.65 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957317 | 0.86 | DAO (0.65) | DAOPARP1HASPINPIM1PDE3B | |
| SCHEMBL3423734 | 0.79 | DAO (1.00) | DAOPARP1KDM5AKDM5CKDM5B | |
| SCHEMBL30474114 | 0.79 | DAO (0.65) | DAOPARP1PDE3BPDE3AHRH4 | |
| SCHEMBL15906825 | 0.79 | DAO (0.65) | DAOPARP1PDE3BPDE3AHRH4 | |
| SCHEMBL25320223 | 0.79 | DAO (0.65) | DAOPARP1PDE3BPDE3AHRH4 | |
| SCHEMBL15272584 | 0.79 | DAO (0.65) | DAOPARP1HASPINPIM1PDE3B | |
| SCHEMBL7494057 | 0.77 | DAO (0.53) | DAOHASPINPIM1PDE3BPDE3A | |
| SCHEMBL12463827 | 0.76 | DAO (0.61) | DAOPARP1HRH4KDM5A | |
| SCHEMBL15270655 | 0.75 | DAO (0.64) | DAOPARP1HRH4KDM5AMAPT | |
| SCHEMBL22016193 | 0.75 | DAO (0.59) | DAOPARP1PDE3BPDE3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | DAO 4523/4885PARP1 1472/4885HASPIN 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.